Published in Invest New Drugs on January 14, 2016
Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res (2008) 1.89
Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther (2003) 1.87
Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol Cancer Ther (2006) 1.37
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. J Clin Oncol (2015) 1.19
Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet (2006) 1.04
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One (2013) 0.86
Human radiolabeled mass balance studies: objectives, utilities and limitations. Biopharm Drug Dispos (2009) 0.86
Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer. J Clin Pharmacol (2015) 0.85
LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. J Pharm Biomed Anal (2013) 0.80